Knowledge of the genetic and regulatory factors that influence energy homeostasis is advancing rapidly. There is increased understanding of the molecular signals that reach the brain with information regarding the current state of energy balance, how those signals are detected by the brain, and key neuronal systems important in translating the information into efferent responses. The identification of molecules that control food intake has generated new targets for drug development in the treatment of obesity. In view of the complexities of the energy control system, therapeutic strategies that target only one site are likely to be less effective than those targeting two or more sites. International Journal of Obesity (2002) 26, Suppl 4, S8 -S10. doi:10.1038/sj.ijo.0802211 Keywords: energy homeostasis; satiety; leptin; insulin; cholecystokinin
The physiology of obesity
The amount of fat in the body (adiposity) is not, as was once thought, a passive result of bad habits or over-indulgence. Rather, it is precisely regulated as part of the process of energy homeostasis, a process whereby energy intake (food intake) is matched to energy expenditure (metabolism and exercise) and the size of the body's energy stores (the fat mass).
The major organ regulating this system is the brain, although multiple organ systems participate in the process. Figure 1 shows how circulating signals related to the size of the fat mass (adiposity signals) are integrated with signals from the gastrointestinal system (satiety signals) to control energy homeostasis. 1 Adiposity signals enter the brain at the level of the hypothalamus. Neural signals from the gastrointestinal system and the liver provide information about the food that is being eaten, for example, the taste of the food, how much the stomach is distended, and the chemical content of the food. These satiety signals are sent to the hindbrain. The brain responds to the hormone signals via integrated neuropeptide pathways, leading to a number of outputs that are directly related to energy homeostasis. These include: neuroendocrine activation from the pituitary gland; motor behaviour (eating, exercise, etc); autonomic activity. In recent years it has become apparent that the autonomic nervous system has a much greater impact than was once thought upon many fundamental processes of metabolism, including lipolysis, the secretion of insulin and glucagon from the pancreas, and glucose synthesis and secretion from the liver.
It is important to note that, while energy expenditure tends to decrease with ageing, mainly because of the absence of occupational activity and extreme physical exertion, energy intake does not tend to decrease to the same extent, for a number of reasons, including lifetime habits. Thus there is a tendency over time for the body weight to increase.
Control of meal size
There is little physiological evidence that appetite and meal initiation are controlled by metabolic or hormonal signals, such as low blood glucose. Rather, the available evidence suggests that, under normal circumstances, meal initiation is based on learned associations, for example, habit and the social environment. Regulation therefore has to involve how much is eaten and there is compelling evidence that meal cessation (that is, meal size) is controlled by pre-absorptive gut signals.
In recent years a mechanism for this regulation has been elucidated. As illustrated in Figure 2 , gastrointestinal peptides provide a signal to tell the brain how much has been eaten, how many calories have accumulated and help to create the feeling of satiety. The best known of these satiety factors is cholecystokinin (CCK). A number of experiments have been carried out in humans in which CCK was given intravenously prior to a test meal and, in every instance, there was a significant reduction of meal size. An important aspect is that CCK is more effective in reducing meal size when the subject has been given a preload, that is, when the stomach is slightly distended, than when no preload is given. 2 Giving CCK can therefore reduce food intake, but does endogenous CCK also contribute to satiety? A recent paper by Beglinger and colleagues 3 shows that administration of the CCK antagonist loxiglumide to humans prior to a test meal was associated with a significant increase in the amount of food eaten. This suggests that endogenous CCK normally acts to limit meal size, as has been shown in several animal species.
Although the size of individual meals can therefore be manipulated, therapies intended to mimic satiety mechanisms are not in themselves likely to be efficacious for weight loss. There are no studies in which CCK has been given on a chronic basis to humans, but animal studies suggest that this would probably not lead to loss of body weight.
Control of body fat
There is strong evidence that key hormonal regulatory signals -the adiposity hormones -control both how much is eaten and how much energy is expended. These hormones circulate in the blood in direct proportion to body fat content. They enter the brain and act on receptors in areas of the hypothalamus known to regulate food intake and energy expenditure. If weight is lost, the hormone levels fall, food intake goes up and energy expenditure is reduced. The opposite occurs when an individual has gained excess weight. Thus body weight tends to be maintained relatively constantly over time.
Insulin was the first compound described to have this effect. Pancreatic insulin secretion is directly proportional to the size of the fat mass. Polonsky has demonstrated that in the basal state and following meals obese people secrete more insulin, although blood glucose is identical in obese and lean individuals. 4 Leptin is another adiposity hormone. It is secreted from white fat, again in direct proportion to the size of the fat mass, although the amount of fat in the cell is not the exact stimulus for its secretion.
Administration of either leptin or insulin directly into the brain causes a dose-dependent reduction of food intake, increased energy expenditure and decreased body weight. This suggests that the brain interprets the signal as if more fat has accumulated in the body. Conversely, reducing the amount of insulin or leptin uniquely in the brain causes increased food intake, decreased energy expenditure and increased body weight; in other words, individuals act as if they are underweight. Insulin has a very short plasma halflife of 2.5 -3 min. It provides a minute to minute update of ongoing metabolic activity via a signal that is directly proportional to total body fat. In contrast, leptin has a half-life of about 45 min and provides a more stable message to the brain about body fat stores. The two together provide a very compelling signal and a therapy that increases leptin or insulin activity selectively in the brain, if this were possible, would be likely to be a successful weight loss strategy.
The reason for this is explained in Figure 3 , which shows how a simple circuit accounts for many pharmacological and genetic findings related to food intake and obesity. Leptin and insulin stimulate neurons in the hypothalamus to produce the neurotransmitter alpha-melanocyte stimulating hormone (alpha-MSH). This acts at a melanocortin receptor in another part of the hypothalamus to reduce food intake. 
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Lack of leptin or of the leptin receptor, in both animals and humans, leads to obesity. Obesity also occurs if the genes for alpha-MSH or for the melanocortin receptor are lacking. This is, therefore, a very potent and important pathway for controlling body weight.
Indeed, of all the genes that are associated with human obesity, the greatest number appears to be associated with this particular network. For example, mutations of the melanocortin-4 receptor have been identified in up to 4% of obese human populations 5 and mutations have also been reported for genes encoding leptin, the leptin receptor, and pro-opiomelanocortin (POMC, the melanocortin precursor). Although most instances of human obesity are polygenic, 6 this system is likely to be important.
Therapeutic implications
Current understanding suggests that those therapies that target receptors 'downstream' of leptin and insulin receptors in the brain are likely to be particularly successful at producing weight loss. Leptin and insulin enter the brain at the arcuate nucleus and activate catabolic pathways (involving, for example, serotonin and noradrenaline) while inhibiting anabolic pathways. There is overwhelming evidence that resistance to leptin and insulin at their transport system through the blood -brain barrier is partly responsible for obesity in many individuals.
In summary, the neuroendocrine control system over energy homeostasis is complex, with multiple possible points of intervention. The placebo effect is large in the treatment of obesity and any therapy must cause more weight loss than placebo. Most treatments that have been tried over the years produce a rapid decrease in body weight before a plateau is reached. This weight loss plateau occurs because, as bodyweight decreases, the metabolic rate decreases and there are reduced levels of adiposity signals feeding back to the brain, which tends to cause increased food intake. Because of the complexity of the energy control system and the many redundancies within it, therapeutic strategies that intervene at only one point in the system will be less effective than those targeting two or more processes. Thus, for example, targeting satiety, with CCK, or targeting adiposity signalling, via insulin or leptin, has only a small effect. However, animal studies have shown that combinations of very low doses of CCK plus insulin or leptin -targeting both satiety and adiposity signalling -have a large effect on reducing body weight.
It is noteworthy that of the drugs currently approved in the United States and Europe, orlistat acts on one process (absorption) while sibutramine acts on two processes (satiety and energy expenditure).
Conclusion
The enormous cost to human health associated with overweight and obesity make it vital that the mechanisms controlling food intake and energy homeostasis be fully elucidated. A more detailed understanding of the pathophysiology of obesity may ultimately lead to the development of more effective weight management therapies.
